Greenwich LifeSciences, Inc. GLSI

$18.70 +35.90% at last close
Market Cap$201.97 million
P/E Ratio—
Div Yield—
Volume1.11M
52-Week Range $7.78$34.10

Analyst Ratings

Consensus
Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
Avg. Price Target
$70.00 (+274.3% upside)

Full GLSI forecast & analyst actions →

Key Stats

Today's Range
$15.73 – $19.28
50-Day Range
$13.38 – $20.31
52-Week Range
$7.78 – $34.10
Volume
1.11 million shs
Average Volume
169K shs
Market Cap
$201.97 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.02%
Days to Cover
1.00

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
13
Exchange
XNAS
Listed
2020-09-25

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.